Every capital-equipment pitch arrives with an ROI sheet, and every one of them is built to sell. They count treatments at full price, assume a schedule you don't have, and quietly omit the three costs that actually decide whether a platform makes money: consumables, post-warranty service, and the opportunity cost of the room and the provider running it.
A device is not a good investment because the technology is impressive. It's a good investment because, at the price your market will pay and the volume you can realistically book, each treatment clears its true variable cost with margin to spare — and the machine pays itself off before the next shiny platform makes it feel obsolete.